Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00938860 · ClinicalTrials.gov registry record · Phase 4
Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 92
- Enrollment target
NCT00938860 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 92 participants.
The verdict
NCT00938860, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 92 participants
- Enrollment target
Study Summary
This study will assess the rates of Sustained Virological Response following anti-viral therapy with Peg-Interferon plus Ribavirin in patients that have been liver transplanted with recurrent Hepatitis C and treated with Neoral or tacrolimus.
Interventions
- DRUG cyclosporin (Neoral)
- DRUG tacrolimus (Prograf)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00938860
The ClinicalTrials.gov registry entry for NCT00938860 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cyclosporin (Neoral) is the first listed.
NCT00938860 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00938860 about?
NCT00938860 is a clinical study titled "Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C". This study will assess the rates of Sustained Virological Response following anti-viral therapy with Peg-Interferon plus Ribavirin in patients that have been liver transplanted with recurrent Hepatitis C and treated with Neoral or tacrolimus.
What is the current status of trial NCT00938860?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 92 participants. The study started on 2009-09. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00938860?
The interventions under investigation include: cyclosporin (Neoral) (DRUG), tacrolimus (Prograf) (DRUG).
Who is sponsoring clinical trial NCT00938860?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.